louferrari

Savient appoints new president and chief executive

pharmafile | July 10, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Ferrari, Savient, cuts 

Savient Pharmaceuticals has appointed Louis Ferrari to the role of president and chief executive for the firm.

Ferrari succeeds Savient’s interim chief executive David Norton, who will continue serving as a member of the Savient board of directors.

“Lou has more than 30 years of leadership experience in the pharmaceutical industry and has been an invaluable member of our senior management team,” said Stephen Jaeger, chairman of Savient. 

Advertisement

Ferrari (pictured) said: “I am honoured to be given the opportunity to take on the role of president and chief executive of Savient during this critical time in the company’s history. Over the past several months, my colleagues and I have been working closely with the board to develop a plan to better position the company for future growth.”

Savient has also announced reorganisation plans and organisational changes to align its operations and budget which sees the company eliminate approximately 35% of its workforce, effective from September.  

In particular, Savient noted that its field force will be restructured to consist of 35 key account managers and three regional business directors. Savient said it does not expect that service levels to patients, doctors or other customers will be impacted by this reduction. 

Related Content

Brandicourt

Sanofi plans R&D jobs cuts in France

Sanofi chief executive Olivier Brandicourt is reported to be planning hundreds of job cuts across …

Counting the true cost of the Cancer Drugs Fund cuts

Leading figures from the pharma industry and cancer charities reacted with dismay to the recent …

NHS sign

Companies braced for new round of cancer cuts

Several treatments that extend the lives of people with cancer are expected to be removed …

The Gateway to Local Adoption Series

Latest content